The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Mon., Jul. 4, 11:37 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #38. Sorrento Therapeutics, Inc. Concortis Biosystems, Corp

Acquirer: Sorrento Therapeutics, Inc. (NASDAQ:SRNE)
Acquiree: Concortis Biosystems, Corp
Details: Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today the entry into a definitive agreement to acquire San Diego-based Concortis Biosystems, Corp. in a deal that provides Sorrento with a comprehensive technology platform for generation of antibody drug conjugates (ADC). Under the terms of the agreement dated November 11, 2013, subject to satisfaction of certain closing conditions, upon closing, Sorrento will issue an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders.

Sorrento Therapeutics is a clinical stage and commercial biopharmaceutical company that delivers therapies to address unmet medical needs. Co. has programs assessing the use of its technologies and products in autoimmune, inflammatory, viral and neurodegenerative diseases. Co.'s segments are: Sorrento Therapeutics, which includes Sofusa®, a drug delivery technology that delivers biologics into the lymphatic system, and resiniferatoxin, a non-opioid-based neurotoxin in clinical trials for late stage cancer pain and moderate to severe osteoarthritis of the knee pain; and Scilex, which includes ZTlido, a lidocaine topical system for the relief of pain associated with post-herpetic neuralgia.

SRNE SEC Filing Email Alerts Service

Open the SRNE Page at The Online Investor »

Company Name: 
Sorrento Therapeutics Inc
Number of ETFs Holding SRNE: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the SRNE Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree SRNE Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
71st percentile
(ranked higher than approx. 71% of all stocks covered)

Analysts' Target Price:
SRNE Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 38 of 83 Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.